Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24669358 | 0.75 | ALDH1A1 (0.45) | ALDH1A1NPC1POLBRAB9APDGFRB | |
| SCHEMBL822694 | 0.75 | MAPT (0.57) | ALDH1A1NPC1POLBRAB9ACYP3A4 | |
| SCHEMBL15935206 | 0.74 | ALDH1A1 (0.43) | ALDH1A1NPC1POLBRAB9APDGFRB | |
| SCHEMBL256353 | 0.73 | MEN1 (0.33) | TSHRMEN1KMT2ACYP2C19MTOR | |
| SCHEMBL22158726 | 0.71 | ALDH1A1 (0.41) | ALDH1A1NPC1POLBRAB9APDGFRB | |
| Quinoline SCHEMBL28042102 | 0.71 | ALDH1A1 (0.68) | ALDH1A1NPC1POLBRAB9APDGFRB | |
| SCHEMBL129937 | 0.70 | CYP2A6 (0.44) | ALDH1A1KDM4EMAPTTSHRLMNA | |
| SCHEMBL16417579 | 0.70 | MAOA (0.31) | — | |
| SCHEMBL10772643 | 0.69 | ALDH1A1 (0.43) | ALDH1A1NPC1POLBRAB9APDGFRB | |
| Quinoline SCHEMBL18804794 | 0.69 | ALDH1A1 (0.94) | ALDH1A1NPC1POLBRAB9ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242511-A1 | FUSED PYRAZOLE AND IMIDAZOLE BASED COMPOUNDS AND USE THEREOF AS GLI1 INHIBITORS | GLIXOGEN THERAPEUTICS LTD. (IL) | 2023-08-03 | — | — | US | disclosed |
| WO-2022263548-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | LEAD DISCOVERY CENTER GMBH (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-4104901-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | Lead Discovery Center GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| US-20210198269-A1 | INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs) | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-07-01 | — | — | US | disclosed |
| WO-2020120420-A1 | METHOD FOR PREPARATION OF PRIMARY AMINE COMPOUNDS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-06-18 | — | — | WO | disclosed |
| EP-2935247-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9765068-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9745291-B2 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme, Inc. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| WO-2012041292-A2 | COMPOUNDS FOR DIAGNOSING NEURODEGENERATIVE DISEASES AT THE RETINA | KLINIKUM DARMSTADT GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012037928-A2 | COMPOUNDS FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISORDERS ON THE OLFACTORY EPITHELIUM | KLINIKUM DARMSTADT GMBH (DE) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012028332-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2012-03-08 | — | — | WO | disclosed |
| EP-2423208-A1 | Pharmaceutically active compounds as Axl inhibitors | Lead Discovery Center GmbH (DE) | 2012-02-29 | — | — | EP | disclosed |
| US-20120007063-A1 | USE OF DIBENZOFURANS AND DIBENZOTHIOPHENES SUBSTITUTED BY NITROGEN-BONDED FIVE-MEMBERED HETEROCYCLIC RINGS IN ORGANIC ELECTRONICS | BASF SE (DE) | 2012-01-12 | — | — | US | disclosed |
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| EP-2210881-A1 | Derivatives of syringolin A | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010081731-A2 | DERIVATIVES OF SYRINGOLIN A | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V (DE) | 2010-07-22 | — | — | WO | disclosed |
| WO-2008055488-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | TGM2, TGM3, TGM1 | ALDH1A1 4170/4885NPC1 3980/4885POLB 2691/4885 |
| US-20120007063-A1 | USE OF DIBENZOFURANS AND DIBENZOTHIOPHENES SUBSTITUTED BY NITROGEN-BONDED FIVE-MEMBERED HETEROCYCLIC RINGS IN ORGANIC ELECTRONICS | DDT, DBF4, POU5F1 | ALDH1A1 1002/4885NPC1 3359/4885POLB 2744/4885 |
| US-20210198269-A1 | INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs) | SLC2A1, SLC2A3, SLC2A4 | ALDH1A1 515/4885NPC1 555/4885POLB 2303/4885 |
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | ALDH1A1 1890/4885NPC1 2147/4885POLB 2703/4885 |
| US-20230242511-A1 | FUSED PYRAZOLE AND IMIDAZOLE BASED COMPOUNDS AND USE THEREOF AS GLI1 INHIBITORS | GLI1, SHH, GLI2 | ALDH1A1 992/4885NPC1 846/4885POLB 3627/4885 |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | ALDH1A1 3825/4885NPC1 3204/4885POLB 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.